FWBI [NASD]
First Wave BioPharma, Inc.
Index- P/E- EPS (ttm)-248.68 Insider Own12.66% Shs Outstand1.00M Perf Week-15.50%
Market Cap4.81M Forward P/E- EPS next Y-5.42 Insider Trans0.00% Shs Float0.87M Perf Month-37.69%
Income-22.30M PEG- EPS next Q-2.90 Inst Own2.00% Short Float / Ratio2.63% / 0.04 Perf Quarter-33.24%
Sales- P/S- EPS this Y99.30% Inst Trans- Short Interest0.02M Perf Half Y-86.19%
Book/sh-9.97 P/B- EPS next Y58.80% ROA-283.80% Target Price72.00 Perf Year-98.40%
Cash/sh1.62 P/C2.83 EPS next 5Y- ROE247.00% 52W Range3.01 - 348.60 Perf YTD-25.28%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-98.69% Beta1.59
Dividend %- Quick Ratio0.40 Sales past 5Y- Gross Margin- 52W Low52.05% ATR0.97
Employees17 Current Ratio0.40 Sales Q/Q- Oper. Margin- RSI (14)43.55 Volatility13.42% 19.09%
OptionableNo Debt/Eq- EPS Q/Q102.70% Profit Margin- Rel Volume0.18 Prev Close4.75
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume523.62K Price4.58
Recom2.00 SMA20-12.04% SMA50-10.56% SMA200-85.39% Volume95,600 Change-3.58%
Feb-07-23 07:00AM
Feb-02-23 07:00AM
Jan-31-23 07:00AM
Jan-30-23 07:00AM
Jan-25-23 07:00AM
07:00AM Loading…
Jan-24-23 07:00AM
Jan-13-23 04:00PM
10:20AM
Jan-09-23 09:10AM
Jan-05-23 09:45AM
Dec-12-22 07:30AM
Dec-05-22 07:00AM
Nov-30-22 07:00AM
Nov-25-22 05:45PM
Nov-22-22 04:15PM
08:00AM Loading…
Nov-21-22 08:00AM
Nov-16-22 07:00AM
Oct-31-22 07:00AM
Oct-11-22 05:30PM
Oct-10-22 07:00AM
Oct-06-22 09:00PM
08:05AM
Sep-28-22 07:00AM
Sep-19-22 07:00AM
Sep-14-22 07:00AM
Sep-07-22 07:00AM
Aug-31-22 07:00AM
Aug-29-22 07:00AM
Aug-25-22 12:00PM
Jul-15-22 08:00AM
07:00AM Loading…
May-17-22 07:00AM
Apr-29-22 04:30PM
Apr-27-22 07:00AM
Mar-31-22 08:15AM
Mar-28-22 04:23PM
Mar-22-22 07:00AM
Mar-08-22 07:00AM
Mar-03-22 07:00AM
Mar-02-22 05:00PM
Mar-01-22 07:00AM
Feb-28-22 08:01AM
Feb-07-22 07:30AM
Jan-17-22 10:30AM
Jan-14-22 11:25AM
09:00AM
Jan-13-22 07:00AM
Jan-07-22 09:16AM
Jan-06-22 07:00AM
Jan-04-22 07:00AM
Dec-27-21 02:00PM
Dec-23-21 11:45AM
Dec-17-21 09:06AM
Dec-13-21 07:00AM
Dec-09-21 07:00AM
Dec-06-21 07:00AM
Nov-30-21 07:00AM
Nov-16-21 07:00AM
Oct-21-21 07:30AM
Oct-19-21 09:24AM
Oct-14-21 09:00AM
Oct-12-21 08:30AM
Oct-04-21 11:45AM
Oct-01-21 12:30PM
Sep-28-21 08:00AM
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.